[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20050208035A1 - Nutritional composition for treating an immune condition - Google Patents

Nutritional composition for treating an immune condition Download PDF

Info

Publication number
US20050208035A1
US20050208035A1 US11/133,588 US13358805A US2005208035A1 US 20050208035 A1 US20050208035 A1 US 20050208035A1 US 13358805 A US13358805 A US 13358805A US 2005208035 A1 US2005208035 A1 US 2005208035A1
Authority
US
United States
Prior art keywords
composition
vitamin
nutrients
present
minerals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/133,588
Inventor
Evelyn Spivey-Krobath
Claude Cavadini
Ferdinand Haschke
Veronique Jaussan
Eduardo Schiffrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050208035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Priority to US11/133,588 priority Critical patent/US20050208035A1/en
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HASCHKE, FERDINAND, CAVADINI, CLAUDE, SCHIFFRIN, EDUARDO, SPIVEY-KROBATH, EVELYN, JAUSSAN, VERONIQUE
Publication of US20050208035A1 publication Critical patent/US20050208035A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • composition is required to address the problems of immune conditions in the elderly as well as in clinical and performance settings, for example, with regard to an athlete recovering from injury.
  • composition that can be used to provide general nutrition to an elderly patient, as well as performance nutrition, e.g., to an athlete, or clinical nutrition to a hospital patient.
  • the present invention provides a composition comprising a new combination of ingredients, including a source of protein, a source of carbohydrate, a source of fat, a probiotic lactic acid bacterium, fructo-oligosaccharides and/or gum acacia.
  • the probiotic lactic acid bacterium is advantageously present in an amount sufficient to help treat an immune condition of a subject who consumes the composition.
  • the invention also provides a method of producing the composition by blending the required nutrients together in the required amounts to form the composition.
  • the invention provides a method of manufacturing a functional food or a medicament for the prevention or treatment of an immune condition by incorporating or including these compositions in the food or medicament.
  • the invention also provides a method of prevention or treatment of an immune condition which comprises administering to a subject in need of such treatment an effective amount of one of the compositions, foods or medicaments described herein.
  • an immune condition represents an ailment selected from the group which comprises an impaired immune response, an inflammatory condition, inflammation, chronic disease (for example arthritis or gastritis), conditions associated with aging and leading to an increase of inflammatory responses.
  • the present invention provides a composition which comprises a source of protein, a source of carbohydrate, a source of fat, a probiotic lactic acid bacterium, fructo-oligosaccharides and/or gum acacia.
  • the one or more probiotic lactic acid bacteria are selected from the group consisting of paracasei and johnsonii bacteria. More preferably, an embodiment of a composition according to the invention comprises one or more probiotic lactic acid bacteria selected from the group which consists of ST11 (deposited under the number NCCMI-2116) and La1 (deposited under the number NCCMI-1225).
  • Advantages in treating immune conditions provided by the probiotic bacteria include prevention or inhibition of diarrhea brought about by pathogenic bacteria; prevention or inhibition of diarrhea, especially infections of intestinal cells by rotavirus; prevention of colonization of the intestine by pathogenic bacteria causing diarrhea; and an ability to adhere to and colonize the intestinal mucosa of a host organism.
  • one or more nutrients or minerals selected from the group consisting of vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium are included in the composition. More preferably, at least two of these nutrients or minerals are included. Even more preferably, at least three of these nutrients or minerals are present. Most preferably it includes all of these minerals or nutrients.
  • Another embodiment of the invention additionally comprises one or more nutrients or minerals selected from the group consisting of calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D. More preferably, it comprises at least two of these nutrients or minerals. Even more preferably, it comprises at least three of these nutrients or minerals. Most preferably all of these minerals or nutrients are present.
  • compositions preferably include gum acacia. It is also desirable to include calcium in the form of milk calcium or calcium derived from milk calcium in the composition, preferably with the nutrients described previously.
  • the following masses or amounts of nutrients or minerals (if present) are included per 300 g of the composition.
  • this is the amount of composition administered per day:
  • the invention further comprises one or more nutrients selected from the following masses or amounts of nutrients or minerals (if present) per 300 g of the composition. Again, this is the amount of composition administered per day:
  • An advantage of the present invention is that it provides a nutritional composition in the form of a powder or dry granulate that can be dissolved instantaneously in water to provide a beverage or soup. It does not require cooking.
  • Another advantage of the present invention is that it provides a single composition that can be adapted and administered simply in a food for the prevention or treatment an immune condition.
  • the composition can be provided in clinical or performance nutrition settings and is particularly suitable for an elderly patient.
  • Yet another advantage of the present invention is that it provides a composition beneficial for diabetics. This is due to the specific composition of macronutrients, protein, carbohydrate and fat which provides a low glycemic index.
  • a nutritional composition comprises a source of protein.
  • the protein source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 26% of the energy.
  • Dietary protein is preferred as a source of protein.
  • the dietary protein may be any suitable dietary protein; for example animal protein (such as milk protein, meat protein or egg protein); vegetable protein (such as soy protein, wheat protein, rice protein, and pea protein); a mixture of free amino acids; or a combination thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.
  • the composition also comprises a source of carbohydrates and a source of fat.
  • a fat source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 23%, of the energy.
  • Lipid making up the fat source may be any suitable fat or fat mixture. Vegetable fat is particularly suitable; for example soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil,. lecithins, and the like. Most preferably it is a mixture of canola and soy oils. Animal fat such as milk fat may also be added if desired.
  • the composition comprises saturated fat which preferably comprises about 1% to about 5%, more preferably 2.5% of the total energy of the product.
  • it comprises monounsaturated fat which preferably comprises about 5% to about 15%, more preferably 9.9% of the total energy of the product.
  • the composition comprises polyunsaturated fat which preferably comprises about 5% to about 15%, more preferably 10.1% of the total energy of the product.
  • the composition comprises linoleic acid which preferably comprises about 5% to about 15%, more preferably 8.5% of the total energy of the product.
  • the composition comprises linoleic acid which preferably comprises about 0.5% to about 5%, more preferably 1.6% of the total energy of the product.
  • the ratio of linoleic acid to linoleic acid is about 3 to about 8, more preferably about 5.3.
  • composition additionally comprises about 10E10 cfu of paracaseii, or johnsonii probiotic lactic acid bacteria and about 6 g of fructooligosaccharide and gum acacia per 300 g of the composition.
  • Dietary fiber may also be added.
  • dietary fiber is present to provide up to about 5% of the energy of the nutritional composition.
  • the dietary fiber may be from any suitable origin, preferably fructooligosaccharide, acacia gum, or a mixture thereof.
  • compositions as described previously.
  • monosodium glutamate may be added as a flavor enhancer.
  • the nutritional composition is preferably enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenized mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a usual food product may be enriched with an embodiment of composition.
  • the amount of the composition added is preferably at least about 0.01% by weight.
  • an embodiment of a method according to the invention comprises the steps of blending the nutrients in the required amounts and extruding the blended mixture. More preferably it includes spray drying the mixture.
  • compositions Two nutritional compositions were made by blending the required constituents. Their compositions are indicated below in table 1. The compositions are intended to be consumed in the form of two oral supplements per day based on enriched beverages or milk product desserts. The total daily dose is intended to be approximately 300 g or 300 ml of composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

A nutritional composition is described for prevention or treatment of an immune condition. The composition includes at least vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc, selenium, fructo-oligosaccharides and/or gum acacia, a probiotic lactic acid bacterium. For example, in an embodiment it comprises per 300 g: 150 IU Vitamin E, 120 mg Vitamin C, 2 mg Vitamin B6, 400 ug Folic acid, 3.8 ug Vitamin B12, 1.5 mg Copper, 15 mg Zinc, 100 ug Selenium, 3 g Fructo-oligosaccharides and/or gum acacia, 10E10 cfu ST11 lactobacillus. Also disclosed are a method for making the nutritional composition, a method for manufacturing a functional food or medicament; and a method of prevention or treatment of an immune condition by administering an effective amount of the composition, functional food or medicament.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application is a continuation of the US national phase of International application PCT/EPO1/13302 filed Nov. 14, 2001, the content of which is expressly incorporated herein by reference thereto.
    • BACKGROUND ART
  • The present invention relates to a nutritional composition for prevention or treatment of an immune condition, a method of production of the composition, use of the composition in the manufacture of a functional food or medicament for the prevention or treatment of an immune condition and a method of treatment of an immune condition which comprises administering an effective amount of the composition.
  • At the turn of the century, Americans older than 65 years old accounted for 4% of the US population. Currently, they account for greater than 12% of the population. However, although they only account for 12% of the US population, they account for greater than 40% of acute hospital bed days, buy greater than 30% of all prescription drugs and spend 30% of the US health budget. Furthermore, it has been estimated that in 2030, greater than 70 million Americans (1:5) will be over the age of 65, and those over 85 are expected to experience the highest percentage increase of all age groups.
  • As the average age of the population increases, obtaining a better understanding of the unique aspects of aging in relation to nutritional needs and treatment is imperative. Many physiologic functions decline progressively throughout adult life and have an impact on nutrition. For instance, a reduction in the number of functioning cells and the resultant slowing of metabolic processes results in a decrease in caloric requirements among the elderly. Also, the reduction in physical activity that generally accompanies aging further decreases energy requirements.
  • Merely decreasing the total caloric intake of an elderly patient may adversely affect their required nutrition. When the total caloric intake is reduced, the remaining food intake must carefully insure a properly balanced intake of proteins, vitamins and minerals. To reduce caloric intake in the elderly, consumption of “empty” calories (i.e. fats) can be reduced and consumption of nutrient-dense foods (i.e. carbohydrates and proteins) can be increased.
  • While the nutritional needs of the mature adult differ from those of an adult, in health care settings, standard nutritional formulae are the primary form of elemental nutrition currently used. Naturally, standard formulae do not take into account the nutritional needs of an elderly patient. Standard products suffer from the problem that they must be supplemented with key micronutrients to compensate for common deficiencies and metabolic changes of an elderly patient. Therefore, a need exists for a nutritional composition which meets the nutritional needs of an elderly patient.
  • In addition to the above problems, a composition is required to address the problems of immune conditions in the elderly as well as in clinical and performance settings, for example, with regard to an athlete recovering from injury.
  • Furthermore, it is known that the effects of diet and nutritional supplements can play a role in improving the survival and quality of life. In particular, a need exists for a nutritional composition which can help to improve health, in particular with regard to an immune condition.
  • Furthermore, it is known that the problem of an impaired immune response can be associated with aging, chronic pathological conditions and/or malnutrition. This problem has been partly addressed by providing nutritional supplements. However, these supplements suffer from the problem that, generally, they are specific for certain ailments and do not provide good nutritional support for patients suffering from a more complicated combination of conditions. This is particularly relevant with respect to an elderly patient. In addition, the increase in the likelihood of chronic disease such as arthritis, gastritis, etc, with age leads to an increase in inflammatory reactions.
  • Furthermore, a need exists for a nutritional composition which addresses the problems associated with infectious diarrhea (rotavirus and bacterial infection), allergy, restoration of and maintenance of gut integrity, bacterial overgrowth, endotoxemia and gut permeability.
    • SUMMARY OF THE INVENTION
  • The present invention addresses and resolves the problems set forth in the previous section. Remarkably, a composition has now been found that can be used to provide general nutrition to an elderly patient, as well as performance nutrition, e.g., to an athlete, or clinical nutrition to a hospital patient.
  • To accomplish this, the present invention provides a composition comprising a new combination of ingredients, including a source of protein, a source of carbohydrate, a source of fat, a probiotic lactic acid bacterium, fructo-oligosaccharides and/or gum acacia. The probiotic lactic acid bacterium is advantageously present in an amount sufficient to help treat an immune condition of a subject who consumes the composition.
  • The invention also provides a method of producing the composition by blending the required nutrients together in the required amounts to form the composition.
  • In addition, the invention provides a method of manufacturing a functional food or a medicament for the prevention or treatment of an immune condition by incorporating or including these compositions in the food or medicament.
  • The invention also provides a method of prevention or treatment of an immune condition which comprises administering to a subject in need of such treatment an effective amount of one of the compositions, foods or medicaments described herein.
    • DETAILED DESCRIPTION OF PREFERRED EMBODIMENT
  • Within the context of this specification the word “comprises” is taken to mean “includes, among other things”. It is not intended to be construed as “consists of” or “only”.
  • Within the context of this specification the term “an immune condition” represents an ailment selected from the group which comprises an impaired immune response, an inflammatory condition, inflammation, chronic disease (for example arthritis or gastritis), conditions associated with aging and leading to an increase of inflammatory responses.
  • The present invention provides a composition which comprises a source of protein, a source of carbohydrate, a source of fat, a probiotic lactic acid bacterium, fructo-oligosaccharides and/or gum acacia.
  • The one or more probiotic lactic acid bacteria are selected from the group consisting of paracasei and johnsonii bacteria. More preferably, an embodiment of a composition according to the invention comprises one or more probiotic lactic acid bacteria selected from the group which consists of ST11 (deposited under the number NCCMI-2116) and La1 (deposited under the number NCCMI-1225).
  • Advantages in treating immune conditions provided by the probiotic bacteria include prevention or inhibition of diarrhea brought about by pathogenic bacteria; prevention or inhibition of diarrhea, especially infections of intestinal cells by rotavirus; prevention of colonization of the intestine by pathogenic bacteria causing diarrhea; and an ability to adhere to and colonize the intestinal mucosa of a host organism.
  • Preferably, one or more nutrients or minerals selected from the group consisting of vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium are included in the composition. More preferably, at least two of these nutrients or minerals are included. Even more preferably, at least three of these nutrients or minerals are present. Most preferably it includes all of these minerals or nutrients.
  • Another embodiment of the invention additionally comprises one or more nutrients or minerals selected from the group consisting of calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D. More preferably, it comprises at least two of these nutrients or minerals. Even more preferably, it comprises at least three of these nutrients or minerals. Most preferably all of these minerals or nutrients are present.
  • These compositions preferably include gum acacia. It is also desirable to include calcium in the form of milk calcium or calcium derived from milk calcium in the composition, preferably with the nutrients described previously.
  • Preferably, the following masses or amounts of nutrients or minerals (if present) are included per 300 g of the composition. Preferably, this is the amount of composition administered per day:
      • Vitamin E: preferably about 1 IU to about 400 IU, most preferably about 120 mg
      • Vitamin C: preferably about 6 mg to about 300 mg, most preferably about 120 mg
      • Vitamin B6: preferably about 0.17 mg to about 3 mg, most preferably about 2 mg
      • Folic acid: preferably about 40 μg to about 800 μg, most preferably about 400 μg
      • Vitamin B12: preferably about 0.24 μg to about 5 μg, most preferably about 3.8 μg
      • Copper: preferably about 0.3 mg to about 3 mg, most preferably about 1.5 mg
      • Zinc: preferably about 1.5 mg to about 15 mg, most preferably about 15 mg
      • Selenium: preferably about 7 μg to about 300 μg, most preferably about 100 μg
      • Fructo-oligosaccharides and/or gum acacia: preferably about 4 g to about 50 g, most preferably about 6 g
      • Lactic acid bacteria: preferably about 10E8 to about 10E12 cfu, most preferably about 10E10 cfu.
  • Preferably, the invention further comprises one or more nutrients selected from the following masses or amounts of nutrients or minerals (if present) per 300 g of the composition. Again, this is the amount of composition administered per day:
      • calcium: about 100 mg to about 300 mg, more preferably about 200 mg;
      • phosphorus: about 50 mg to about 615 mg, more preferably about 150 mg;
      • magnesium: about 110 mg to about 210 mg, more preferably about 60 mg;
      • vitamin A: about 1000 IU to about 1500 IU, more preferably about 1333 IU;
      • vitamin D: about 50 IU to about 150 IU, more preferably about 100 IU;
      • vitamin E: about 5.0 IU to about 150 IU, more preferably about 120 IU;
      • vitamin C: about 30 mg to about 500 mg, more preferably about 120 mg;
      • vitamin B1: about 0.1 mg to about 2 mg, more preferably about 0.25 mg;
      • vitamin B2: about 0.1 mg to about 0.6 mg, more preferably about 0.3 mg;
      • niacin: about 1.5 mg to about 7.2 mg, more preferably about 3 mg;
      • vitamin B6: about 1.0 mg to about 3.0 mg, more preferably about 2 mg;
      • folic acid: about 200 μg to about 600 μg, more preferably about 400 μg;
      • vitamin B12: about 1.5 μg to about 4.5 μg, more preferably about 3.8 μg;
      • iron: about 2.0 mg to about 5 mg, more preferably about 2.75 mg; and
      • zinc: about 10 mg to about 20 mg, more preferably about 15 mg.
  • An advantage of the present invention is that it provides a nutritional composition in the form of a powder or dry granulate that can be dissolved instantaneously in water to provide a beverage or soup. It does not require cooking.
  • Another advantage of the present invention is that it provides a single composition that can be adapted and administered simply in a food for the prevention or treatment an immune condition. The composition can be provided in clinical or performance nutrition settings and is particularly suitable for an elderly patient.
  • Yet another advantage of the present invention is that it provides a composition beneficial for diabetics. This is due to the specific composition of macronutrients, protein, carbohydrate and fat which provides a low glycemic index.
  • Additional features and advantages of the present invention are described in, and will be apparent from the description of the presently preferred embodiments which are set out below.
  • For the purposes of clarity and a concise description features are described herein as part of the same or separate embodiments, however it will be appreciated that the scope of the invention may include embodiments having combinations of all or some of the features described.
  • In an embodiment, a nutritional composition comprises a source of protein. The protein source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 26% of the energy. Dietary protein is preferred as a source of protein. The dietary protein may be any suitable dietary protein; for example animal protein (such as milk protein, meat protein or egg protein); vegetable protein (such as soy protein, wheat protein, rice protein, and pea protein); a mixture of free amino acids; or a combination thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.
  • The composition also comprises a source of carbohydrates and a source of fat. A fat source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 23%, of the energy. Lipid making up the fat source may be any suitable fat or fat mixture. Vegetable fat is particularly suitable; for example soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil,. lecithins, and the like. Most preferably it is a mixture of canola and soy oils. Animal fat such as milk fat may also be added if desired.
  • Preferably the composition comprises saturated fat which preferably comprises about 1% to about 5%, more preferably 2.5% of the total energy of the product. Preferably it comprises monounsaturated fat which preferably comprises about 5% to about 15%, more preferably 9.9% of the total energy of the product. Preferably the composition comprises polyunsaturated fat which preferably comprises about 5% to about 15%, more preferably 10.1% of the total energy of the product. Preferably the composition comprises linoleic acid which preferably comprises about 5% to about 15%, more preferably 8.5% of the total energy of the product. Preferably the composition comprises linoleic acid which preferably comprises about 0.5% to about 5%, more preferably 1.6% of the total energy of the product. Preferably the ratio of linoleic acid to linoleic acid is about 3 to about 8, more preferably about 5.3.
  • A source of carbohydrate preferably provides about 40% to about 80%, more preferably about 51% of the energy of the nutritional composition. Any suitable carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, or a mixture thereof.
  • This embodiment of the composition additionally comprises about 10E10 cfu of paracaseii, or johnsonii probiotic lactic acid bacteria and about 6 g of fructooligosaccharide and gum acacia per 300 g of the composition.
  • Dietary fiber may also be added. Preferably dietary fiber is present to provide up to about 5% of the energy of the nutritional composition. The dietary fiber may be from any suitable origin, preferably fructooligosaccharide, acacia gum, or a mixture thereof.
  • Additional suitable vitamins and minerals are included in the composition as described previously. Also, monosodium glutamate may be added as a flavor enhancer.
  • The nutritional composition is preferably enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenized mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • Alternatively, a usual food product may be enriched with an embodiment of composition. For example, a fermented milk, a yogurt, a fresh cheese, a renneted milk, an article of confectionery, for example a sweet or sweetened beverage, a confectionery bar, breakfast cereal flakes or bars, a drink, milk powder, soy-based product, non-milk fermented product or a nutritional supplement for clinical nutrition. Then, the amount of the composition added is preferably at least about 0.01% by weight.
  • Preferably, an embodiment of a method according to the invention comprises the steps of blending the nutrients in the required amounts and extruding the blended mixture. More preferably it includes spray drying the mixture.
    • EXAMPLES
  • The following examples are given by way of illustration only and in no way should be construed as limiting the subject matter of the present application. Percentages and parts are by weight unless otherwise indicated.
    • Examples 1 and 2 Nutritional Compositions
  • Two nutritional compositions were made by blending the required constituents. Their compositions are indicated below in table 1. The compositions are intended to be consumed in the form of two oral supplements per day based on enriched beverages or milk product desserts. The total daily dose is intended to be approximately 300 g or 300 ml of composition.
    TABLE I
    Daily dose 300 ml/day Daily dose 300 ml/day
    Energy 480 kcal 300 kcal
    (1.6 kcal/ml) (1.0 kcal/ml)
    P/L/C % TEI 26%/24%/51% 28%/30%/42%
    Protein g/100 ml 10.5 7.0
    (with 6.25 g
    soy protein)
    Fat g/100 ml 4.16 3.3
    Carbohydrate g/100 ml 20.6 10.5
    in daily dose per 300 ml per 300 ml
    Na mg 188 188
    K mg 350 350
    Cl mg 290 290
    Ca mg 200 200
    P mg 150 150
    Ca/P ratio 1.3 1.3
    Mg mg 60 60
    Mn μg 495 495
    A IU 1333 1333
    D IU 100 100
    E IU 120 150
    K1 μg 13.8 13.8
    C mg 120 120
    B1 mg 0.25 0.25
    B2 mg 0.3 0.3
    Niacin mg 3 3
    B6 mg 2.0 2.0
    Folic acid μg 400 600
    Panto mg 1.00 1.00
    B12 μg 3.8 10.0
    Biotin μg 7.5 7.5
    Fe mg 2.75 2.75
    I μg 75 75
    Cu mg 1.5 1.5
    Zn mg 15 6
    Se μg 100 100
    Cr μg 12.5 12.5
    Mo μg 18.75 18.75
    Inulin & FOS blend 6 6
    (30:70 blend) g
    Lactobacillus cfu/serving Paracaseii 1010 Johnsonii 1010
  • It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that all such changes and modifications be covered by the appended claims.

Claims (21)

1. A nutritional composition comprising a source of protein, a source of carbohydrate, a source of fat, a probiotic lactic acid bacterium and additionally a fructo-oligosaccharide or inulin, wherein the protein, carbohydrate and fat sources provide energy to a subject who consumes the composition, with the protein source providing about 5% to 55% of the energy, the carbohydrates source providing about 40% to 80% of the energy and the fat source providing about 5% to 55% of the energy, wherein the total amount of energy provided by the protein, carbohydrate and fat sources is 100%, and the probiotic lactic acid bacterium is present in an amount sufficient to help treat an immune condition of the subject.
2. The composition of claim 1, wherein the probiotic lactic acid bacterium comprises one or more probiotic lactic acid bacterium selected from the group consisting of paracasei and johnsonii bacteria, and is present in an amount of about 10E8 to 10E12 cfu.
3. The composition of claim 2 wherein the lactic acid bacterium is selected from the group consisting of ST11 (deposited under the number NCCMI-2116) and La1 (deposited under the number NCCMI-1225).
4. The composition of claim 1 which further comprises one or more of gum acacia, dietary fiber, a flavor enhancer, nutrients or minerals.
5. The composition of claim 4 wherein nutrients or minerals selected from the group consisting of vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium are present in the composition.
6. The composition of claim 5 wherein at least three of the recited nutrients or minerals are present in the composition.
7. The composition of claim 5 wherein one or more nutrients or minerals selected from the group consisting of calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D are also present in the composition.
8. The composition of claim 7 wherein at least three of the recited nutrients or minerals are present in the composition.
9. The composition of claim 1 which contains the fructo-oligosaccharide and gum acacia.
10. The composition of claim 1 wherein calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D are present in the composition.
11. The composition of claim 9 wherein the calcium is in the form of milk calcium or calcium derived from milk calcium.
12. The composition of claim 4 wherein the nutrients or minerals, if present, are included in the following masses or amounts per 300 g of the composition:
Vitamin E: about 1 IU to about 400 IU,
Vitamin C: about 6 mg to about 300 mg,
Vitamin B6: about 0.17 mg to about 3 mg,
Folic acid: about 40 μg to about 800 μg,
Vitamin B12: about 0.24 mg to about 5 mg,
Copper: about 0.3 mg to about 3 mg,
Zinc: about 1.5 mg to about 15 mg,
Selenium: about 7 μg to about 300 μg,
Fructo-oligosaccharides and/or gum acacia: about 4 g to about 50 g,
Lactic acid bacteria: about 10E8 to about 10E12 cfu.
13. The composition of claim 4 wherein the nutrients or minerals, if present, are included in the following masses or amounts per 300 g of the composition:
calcium: about 100 mg to about 300 mg,
phosphorus: about 50 mg to about 615 mg,
magnesium: about 110 mg to about 210 mg,
vitamin A: about 1000 IU to about 1500IU),
vitamin D: about 50 IU to about 150 IU,
vitamin E: about 5.0 IU to about 150 IU,
vitamin C: about 30 mg to about 500 mg,
vitamin B1: about 0.1 mg to about 2 mg,
vitamin B2: about 0.1 mg to about 0.6 mg,
niacin: about 1.5 mg to about 7.2 mg,
vitamin B6: about 1.0 mg to about 3.0 mg,
folic acid: about 200 μg to about 600 μg,
vitamin B12: about 1.5 μg to about 4.5 μg,
iron: about 2.0 mg to about 5 mg,
zinc: about 10 mg to about 20 mg.
14. A method of producing the composition of claim 1 which comprises blending the required nutrients together in the required amounts to form the composition.
15. The method of claim 14 which further comprises extruding the blended mixture or spray drying the mixture to a dry solid.
16. The composition produced by the method of claim 15.
17. A method of manufacturing a functional food or a medicament for the prevention or treatment of an immune condition which comprises adding or incorporating an effective amount of the composition of claim 1 into a food or medicament to form the functional food or medicament.
18. The functional food or medicament produced by the method of claim 16.
19. A method of prevention or treatment of an immune condition which comprises administering the functional food or medicament of claim 18 to a subject in need of such treatment in an amount effective to treat such condition.
20. A method of prevention or treatment of an immune condition which comprises administering the composition of claim 16 to a subject in need of such treatment in an amount effective to treat such condition.
21. A method of prevention or treatment of an immune condition which comprises administering the composition of claim 1 to a subject in need of such treatment in an amount effective to treat such condition.
US11/133,588 2000-11-14 2005-05-19 Nutritional composition for treating an immune condition Abandoned US20050208035A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/133,588 US20050208035A1 (en) 2000-11-14 2005-05-19 Nutritional composition for treating an immune condition

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0027761.6A GB0027761D0 (en) 2000-11-14 2000-11-14 Nutritional composition for an immune condition
GB0027761.6 2000-11-14
PCT/EP2001/013302 WO2002039834A1 (en) 2000-11-14 2001-11-14 Nutritional composition for an immune condition
US10/436,477 US6929793B2 (en) 2000-11-14 2003-05-13 Nutritional composition for treating an immune condition
US11/133,588 US20050208035A1 (en) 2000-11-14 2005-05-19 Nutritional composition for treating an immune condition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/436,477 Continuation US6929793B2 (en) 2000-11-14 2003-05-13 Nutritional composition for treating an immune condition

Publications (1)

Publication Number Publication Date
US20050208035A1 true US20050208035A1 (en) 2005-09-22

Family

ID=9903140

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/436,477 Expired - Lifetime US6929793B2 (en) 2000-11-14 2003-05-13 Nutritional composition for treating an immune condition
US11/133,588 Abandoned US20050208035A1 (en) 2000-11-14 2005-05-19 Nutritional composition for treating an immune condition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/436,477 Expired - Lifetime US6929793B2 (en) 2000-11-14 2003-05-13 Nutritional composition for treating an immune condition

Country Status (20)

Country Link
US (2) US6929793B2 (en)
EP (1) EP1339294B2 (en)
JP (1) JP2004513898A (en)
KR (1) KR20030051802A (en)
CN (2) CN1503632A (en)
AT (1) ATE336909T1 (en)
AU (2) AU2186002A (en)
BR (1) BR0115311A (en)
CA (1) CA2427385C (en)
DE (1) DE60122570T3 (en)
ES (1) ES2269514T5 (en)
GB (1) GB0027761D0 (en)
IL (1) IL155674A (en)
MX (1) MXPA03004268A (en)
NO (1) NO326348B1 (en)
PL (1) PL201161B1 (en)
RU (1) RU2289955C2 (en)
UA (1) UA78196C2 (en)
WO (1) WO2002039834A1 (en)
ZA (1) ZA200304605B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278799A1 (en) * 2008-01-10 2010-11-04 Nutri Co., Ltd. Composition for Improving Nutritional Status, Reducing Frequency of Fever and/or Increasing Immunocompetence of the Elderly
WO2012170047A2 (en) * 2010-07-13 2012-12-13 Hero Nutritionals, LLC Chewable supplement with live microorganisms

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
AU2003223971A1 (en) * 2002-04-09 2003-10-20 Societe Des Produits Nestle S.A. La1 - the genome of a lactobacillus strain
JP2004059488A (en) * 2002-07-29 2004-02-26 Asahi Food & Healthcare Ltd Lactobacillus intestinal disorder controlling composition and food
WO2004017979A2 (en) * 2002-08-16 2004-03-04 Finzelberg Gmbh & Co. Kg Medicament, food supplement, and fodder additive
GB2395627B (en) * 2002-11-21 2006-05-10 Hewlett Packard Co Detector
ATE508648T1 (en) 2003-07-15 2011-05-15 Nestec Sa HIGH CALORIES AND FIBER LIQUID FOOD COMPOSITION FOR THE INTESTINAL HEALTH OF ELDERLY PATIENTS
GB0330009D0 (en) 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
US20050245398A1 (en) * 2004-04-29 2005-11-03 Healthy Soils, Inc. Biological composition for enhancing vegetation growth
WO2006012536A2 (en) * 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US20100233312A9 (en) * 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
PL2277524T3 (en) 2005-09-28 2016-06-30 Nordic Rebalance As Treatment of IBS using both probiotic bacteria and fermented cereal as treatment effectors
CN101325960B (en) * 2005-10-06 2012-05-30 普罗比公司 Use of lactobacillus for treatment of virus infections
CN101351124B (en) * 2005-12-29 2014-09-03 希尔氏宠物营养品公司 Method for modifying gut flora in animals
MX2008010440A (en) * 2006-02-13 2008-11-12 Mcneil Nutritionals Llc Lactose-reduced dairy compositions and related methods.
US7951385B2 (en) 2006-05-28 2011-05-31 Cipla Medpro Research And Development (Pty) Ltd. Probiotic strain and antimicrobial peptide derived therefrom
US20080038432A1 (en) * 2006-08-14 2008-02-14 Hoffman Andrew J Food Additive Comprising at Least One Fiber Source and at Least One Monosaccharide or Sugar Alcohol
EP1992351B1 (en) 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii for prevention of postsurgical infection
WO2009004409A1 (en) * 2007-06-29 2009-01-08 Sirc - Natural & Dietetic Foods S.R.L. Preparations contaning microorganisms
IES20080719A2 (en) * 2007-09-21 2009-05-13 Kerry Group Services Int Ltd A probiotic composition
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
WO2010008491A2 (en) * 2008-06-25 2010-01-21 Ritter Natural Sciences, Llc Lactose compositions with decreased lactose content
US20100004334A1 (en) * 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
MX2011007190A (en) 2009-01-02 2011-07-19 Nestec Sa Food compositions having a realistic meat-like appearance, feel and texture.
US8785160B2 (en) * 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
AU2010218439B2 (en) 2009-02-24 2016-10-20 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US20100233347A1 (en) * 2009-03-13 2010-09-16 Uhrhan Richard B Food compositions having a realistic meat-like appearance, feel, and texture
CN101828718B (en) * 2010-04-29 2012-12-26 北京世纪劲得保健品有限公司 High-fiber fruit and vegetable nutrition package and preparation method thereof
US20130178450A1 (en) 2010-05-26 2013-07-11 Nestec Sa Methods for increasing the production or activity of catalase
EP2397145A1 (en) * 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 and immune disorders
JP6207157B2 (en) * 2010-09-24 2017-10-04 株式会社 バイオエルティ Pharmaceutical composition for treatment and prevention of Th3 march related diseases
MX348898B (en) 2011-01-25 2017-07-03 Nestec Sa Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals.
CA2825338C (en) * 2011-02-07 2015-11-17 Abbott Laboratories Nutritional products comprising beta-hydroxy-beta-methylbutyrate
US10010566B2 (en) 2011-03-18 2018-07-03 NestecSA Compositions and methods useful for ameliorating age related maladies
CN103596563A (en) 2011-04-15 2014-02-19 雀巢产品技术援助有限公司 Methods for regulating Sirtuin gene expression
RU2748839C2 (en) 2011-06-20 2021-05-31 Х.Дж. Хайнц Компани Брэндс Ллк Compositions, methods and kits for stimulating the mucosal immune system
RU2485964C1 (en) * 2012-01-10 2013-06-27 Сергей Александрович Староверов Immunostimulating composition for animals
US20140037813A1 (en) * 2012-08-02 2014-02-06 Mead Johnson Nutrition Company Nutritional creamer composition
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
AU2014225786B2 (en) 2013-03-08 2017-10-12 Axiom Foods, Inc. Rice protein supplements
PT2994150T (en) 2013-05-10 2019-06-14 Heinz Co Brands H J Llc Probiotics and methods of use
CN103478716B (en) * 2013-09-23 2016-04-13 南昌大学 A kind of preparation method with the functional food of develop immunitypty effect
EP3082474A1 (en) * 2013-12-20 2016-10-26 Nestec S.A. Nutritional compositions for reducing intestinal pathogens
EP3151689A1 (en) * 2014-04-25 2017-04-12 Nexira International Use of a composition comprising arabic gum (ag) for improving gut impermeability
ES2820574T3 (en) * 2014-09-23 2021-04-21 Dom Terry Int S R L Inulin-based prebiotic preparation
CN104432104A (en) * 2014-11-05 2015-03-25 江南大学 Preparation method of salty high-protein probiotic nutrition bar
US20160165927A1 (en) 2014-11-25 2016-06-16 Nestec Sa Methods and compositions for promoting lean body mass and minimize body fat gain and managing weight
US20160143324A1 (en) 2014-11-25 2016-05-26 Nestec Sa Methods and compositions for preserving lean body mass and promoting fat loss during weight loss
JP6334067B2 (en) 2015-08-25 2018-05-30 株式会社日本触媒 Cement additive, cement composition, and raw material for cement additive
CN105661017A (en) * 2016-02-03 2016-06-15 程雪娇 Livestock feed and preparation method
US9855305B2 (en) 2016-03-29 2018-01-02 Companion Therapeutics Llc Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors
CN110868870A (en) 2017-05-12 2020-03-06 艾斯姆食品公司 Rice products and systems and methods for making same
EP3849334A1 (en) 2018-10-18 2021-07-21 Hill's Pet Nutrition, Inc. Pet food compositions
JP2022511693A (en) 2018-12-13 2022-02-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー How to Improve Metabolic Health in Animals
EP3893662A1 (en) 2018-12-13 2021-10-20 Société des Produits Nestlé S.A. Methods for increasing fat oxidation or energy expenditure or satiety in an animal
PL3911341T3 (en) 2019-01-16 2023-05-02 N.V. Nutricia Fermented formula with non-digestible oligosaccharides for use in rotavirus induced infection
MX2022006412A (en) 2019-12-19 2022-08-02 Nestle Sa Method for dyeing keratinous material, comprising the use of an organosilicon compound, a chromophoric compound, a modified fatty acid ester and a sealing reagent ii.
CN111329046A (en) * 2020-03-13 2020-06-26 上海复旦奥医医学科技有限公司 Special clinical nutrition formula for nasopharyngeal carcinoma and preparation method thereof
AU2021336099A1 (en) 2020-09-03 2023-02-23 Societe Des Produits Nestle Sa Compositions and methods for providing health benefits in an animal
AU2021337209A1 (en) 2020-09-04 2023-02-23 Societe Des Produits Nestle Sa Compositions and methods for providing health benefits in an animal
EP4228427A1 (en) 2020-12-11 2023-08-23 Société des Produits Nestlé S.A. Compositions and methods for pet food
US20230165277A1 (en) 2021-11-29 2023-06-01 Société des Produits Nestlé S.A. Methods and compositions for providing a health benefit in an animal
US20230165281A1 (en) 2021-11-29 2023-06-01 Société des Produits Nestlé S.A. Methods and compositions for providing a health benefit in an animal
CN114848682A (en) * 2022-03-11 2022-08-05 中南大学湘雅三医院 Vitamin B6+ probiotic mixture and application thereof in preparation of medicines for relieving stress-related secondary injury and aseptic inflammation
WO2024057113A1 (en) 2022-09-13 2024-03-21 Societe Des Produits Nestle Sa Methods for providing and determining an efficacious weight loss diet for a canine
US20240081374A1 (en) 2022-09-14 2024-03-14 Société des Produits Nestlé S.A. Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147668A (en) * 1987-08-21 1992-09-15 Munk Werner Georg Process of producing a reconstitutable solid lactic acid dried product
US5185321A (en) * 1989-12-13 1993-02-09 Nestec S.A. Process for producing immunostimulants
US5882704A (en) * 1994-04-27 1999-03-16 Fuji Oil Company Limited Process for the production of cream cheese-like products
US6093425A (en) * 1997-11-21 2000-07-25 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54129163A (en) 1978-03-28 1979-10-06 Fujiya Kk Production of instant yogurt powder
JP3347381B2 (en) * 1993-01-27 2002-11-20 協和醗酵工業株式会社 Pet food
US5565630A (en) 1993-11-17 1996-10-15 Monaghan Medical Corporation Peak flow meter
JPH08126473A (en) * 1994-09-08 1996-05-21 Fuji Oil Co Ltd Oily composition, its production and oily coated confectionery using the same
US6241983B1 (en) * 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
AUPN881396A0 (en) * 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
DE69624805T3 (en) * 1996-07-31 2007-01-04 Raffinerie Tirlemontoise, S.A. Fructan and / or polydextrose containing milk product powders; Process for their preparation and use thereof
JP4065038B2 (en) 1996-08-07 2008-03-19 カルピス株式会社 Computational workload stress relievers
TR200000021T2 (en) * 1997-07-05 2001-01-22 Societe Des Produits Nestle S.A. Absorption of minerals by intestinal cells.
CN1208620A (en) * 1997-08-15 1999-02-24 陈秀枢 Composite contg. bacterium bifidum and lactobacillus
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
US6117477A (en) * 1998-03-18 2000-09-12 Kal Kan Foods, Inc. Multicomponent food product and methods of making and using the same
CA2340926A1 (en) * 1998-08-21 2000-03-02 Maxwell John Strong Composition
ES2251755T3 (en) * 1998-12-15 2006-05-01 Societe Des Produits Nestle S.A. FIBER MIX FOR ENTERAL COMPOSITION.
CA2281463A1 (en) * 1999-08-26 2001-02-26 Stanley H. Zlotkin Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
GB0100273D0 (en) * 2001-01-08 2001-02-14 Nestle Sa Nutritional composition for a bone condition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147668A (en) * 1987-08-21 1992-09-15 Munk Werner Georg Process of producing a reconstitutable solid lactic acid dried product
US5185321A (en) * 1989-12-13 1993-02-09 Nestec S.A. Process for producing immunostimulants
US5882704A (en) * 1994-04-27 1999-03-16 Fuji Oil Company Limited Process for the production of cream cheese-like products
US6093425A (en) * 1997-11-21 2000-07-25 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278799A1 (en) * 2008-01-10 2010-11-04 Nutri Co., Ltd. Composition for Improving Nutritional Status, Reducing Frequency of Fever and/or Increasing Immunocompetence of the Elderly
US10568906B2 (en) 2008-01-10 2020-02-25 Nutri Co., Ltd. Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of the elderly
WO2012170047A2 (en) * 2010-07-13 2012-12-13 Hero Nutritionals, LLC Chewable supplement with live microorganisms
WO2012170047A3 (en) * 2010-07-13 2014-04-03 Hero Nutritionals, LLC Chewable supplement with live microorganisms

Also Published As

Publication number Publication date
PL362438A1 (en) 2004-11-02
CA2427385A1 (en) 2002-05-23
JP2004513898A (en) 2004-05-13
EP1339294B2 (en) 2015-01-21
DE60122570T2 (en) 2007-09-20
ES2269514T5 (en) 2015-04-01
NO20032129L (en) 2003-07-11
UA78196C2 (en) 2007-03-15
EP1339294B1 (en) 2006-08-23
BR0115311A (en) 2004-01-06
AU2186002A (en) 2002-05-27
CN1503632A (en) 2004-06-09
KR20030051802A (en) 2003-06-25
US20040005305A1 (en) 2004-01-08
IL155674A0 (en) 2003-11-23
ZA200304605B (en) 2004-09-13
PL201161B1 (en) 2009-03-31
NO20032129D0 (en) 2003-05-12
WO2002039834A1 (en) 2002-05-23
CN103181564A (en) 2013-07-03
RU2289955C2 (en) 2006-12-27
MXPA03004268A (en) 2004-04-21
CA2427385C (en) 2010-05-04
GB0027761D0 (en) 2000-12-27
EP1339294A1 (en) 2003-09-03
NO326348B1 (en) 2008-11-17
DE60122570T3 (en) 2015-05-21
ES2269514T3 (en) 2007-04-01
US6929793B2 (en) 2005-08-16
AU2002221860B2 (en) 2006-08-10
IL155674A (en) 2005-07-25
ATE336909T1 (en) 2006-09-15
DE60122570D1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
US6929793B2 (en) Nutritional composition for treating an immune condition
AU2002221860A1 (en) Nutritional composition for an immune condition
RU2277355C2 (en) Food formula to improve protein accumulation in muscles
JP6285108B2 (en) Probiotics in pre-operative and / or post-operative environments
US9884033B2 (en) Amino acid supplementation for a healthy microbiota ecosystem
EP1351584A2 (en) Nutritional composition for a bone condition
EP2627196B1 (en) Dairy based smoothie for stimulating growth in children
WO2024185888A1 (en) Nutrition-adjusted food and production method for same
CN112806577B (en) Prebiotic probiotic synergistic combinations for butyric acid production
CN112753776A (en) Milk powder for protecting intestines and stomach and preparation method thereof
Lloyd US whey products and child nutrition

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SPIVEY-KROBATH, EVELYN;CAVADINI, CLAUDE;HASCHKE, FERDINAND;AND OTHERS;REEL/FRAME:016591/0367;SIGNING DATES FROM 20030429 TO 20030510

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION